Endovascular Aneurysm Repair (EVAR) Market Size, Share, Growth, and Industry Analysis, By Type (Abdominal Aortic Aneurysm (AAA),Thoracic Aortic Aneurysm (TAA)), By Application (Hospitals,Clinics,Ambulatory Surgical Centres), Regional Insights and Forecast to 2035

Endovascular Aneurysm Repair (EVAR) Market Overview

The global Endovascular Aneurysm Repair (EVAR) Market is forecast to expand from USD 3357.94 million in 2026 to USD 3557.74 million in 2027, and is expected to reach USD 5657.72 million by 2035, growing at a CAGR of 5.95% over the forecast period.

Endovascular Aneurysm Repair (EVAR) procedures account for nearly 70.1% of abdominal aortic aneurysm (AAA) repairs globally, making it the dominant intervention method. Hospitals are the largest service providers, performing more than 75.2% of EVAR procedures, while ambulatory surgical centres contribute about 24.8%. Infrarenal aneurysms make up about 79.3% of cases treated with EVAR devices, while pararenal aneurysms account for 20.7%, requiring more advanced graft technologies. Open surgical repair continues to be used in 29.9% of aneurysm cases, but the preference for minimally invasive repair drives EVAR dominance. Device usage is dominated by endografts, which represent 58.9% of the product share, while delivery systems and ancillary tools cover the remaining percentage. Procedure volumes vary widely across centres, ranging from 7 to 76 EVAR procedures annually, highlighting significant disparities in adoption levels.

In the USA, EVAR dominates with over 70% of all abdominal aortic aneurysm repairs, while open surgical repair accounts for less than 30%. Median hospital volumes show around 40 procedures per year, with ranges between 21 and 65 depending on centre capacity. Intact AAA repairs through EVAR account for 65.4%, while ruptured AAA cases treated with EVAR remain at 29.1%. Hospitals perform 75% of cases, with the rest managed by ambulatory surgical centres. Infrarenal aneurysms account for about 79% of treated cases, while pararenal aneurysms make up nearly 21%, reflecting growing adoption of fenestrated and branched grafts for complex anatomies.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Around 70% of global aneurysm repair cases use EVAR procedures, reflecting increasing preference over open repair.
• Major Market Restraint: Endoleaks affect approximately 10–20% of EVAR cases, leading to reinterventions and higher healthcare burden.
• Emerging Trends: Fenestrated and branched EVAR cases grew from 335 in 2011 to over 2,100 annually by 2023.
• Regional Leadership: North America leads the global market, contributing 40.2% of total EVAR procedures.
• Competitive Landscape: Endografts hold 58.9% of device share, with delivery systems accounting for the remainder.
• Market Segmentation: Infrarenal aneurysms dominate with 79.3% share, compared to pararenal at 20.7%.
• Recent Development: Median EVAR centre volumes dropped from 24 cases per year in 2011 to 20 cases per year in 2021.

EVAR Market Latest Trends

Recent EVAR Market Trends reveal strong growth in minimally invasive aneurysm repair techniques. EVAR adoption reached 70.1% of all AAA cases globally, driven by lower perioperative mortality and shorter recovery times. Hospitals remain the leading providers, carrying out over 75% of total procedures, while ambulatory surgical centres contribute around 25%. Device share is dominated by endografts, accounting for 58.9%, while ancillary delivery systems make up the rest. Infrarenal aneurysms comprise 79.3% of procedures, with pararenal cases expanding due to fenestrated and branched graft technologies. Complex EVAR adoption is accelerating, with fenestrated and branched EVAR procedures rising from 335 in 2011 to more than 2,100 in 2023. Intact AAA repairs account for 65.4% of EVAR cases, while ruptured aneurysms account for 29.1%. Median case volumes show significant variation across centres, ranging between 7 and 76 procedures annually, reflecting differences in hospital specialization and patient access. The demand for advanced imaging technologies, 3D planning systems, and percutaneous EVAR procedures is also increasing, as hospitals aim to reduce complication rates, especially endoleaks that occur in 10–20% of cases.

EVAR Market Dynamics

The EVAR Market dynamics describe the interplay of drivers, restraints, opportunities, and challenges that shape growth, adoption, and innovation across global healthcare systems. In 2025, the EVAR Market is projected at over 400,000 global procedures annually, with procedural distribution reflecting approximately 70–75% Abdominal Aortic Aneurysm (AAA) cases and 25–30% Thoracic Aortic Aneurysm (TAA) cases. Drivers include the growing prevalence of aortic aneurysms, with AAA affecting 4–8% of men over 65 years, and improvements in minimally invasive stent graft technology that lower perioperative mortality to 1–2% compared to 4–5% for open repair. Restraints emerge from anatomical complexity, with nearly 20.7% of AAA patients requiring advanced fenestrated or branched devices not universally available, and follow-up costs associated with 100% surveillance imaging at 1, 6, and 12 months. Opportunities are present in outpatient and Ambulatory Surgical Centre (ASC) adoption, where same-day discharge rates can exceed 60–70%, reducing hospitalization time from 3–7 days in hospitals. Challenges persist in addressing high costs of stent-grafts, averaging USD 10,000–15,000 per unit, and managing late complications such as endoleaks, observed in up to 20–25% of patients within 5 years, requiring secondary interventions.

DRIVER

"Aging population and improved imaging-based aneurysm detection."

Globally, aneurysms occur in about 2.5% of individuals over 65 years, creating rising demand for EVAR. Among AAA cases, 70% are treated with EVAR due to better outcomes compared to open repair. Hospitals report shorter recovery times and reduced mortality for EVAR patients compared to open surgical repair. Screening programs contribute significantly, with nearly 65% of aneurysms now detected before rupture. The adoption of fenestrated and branched stent grafts further expands the patient pool by addressing 20.7% of pararenal aneurysm cases, once deemed inoperable.

RESTRAINT

"Complications and high costs of EVAR procedures."

Endoleaks are seen in 10–20% of EVAR patients, leading to repeat procedures. Graft migration and device failure contribute to complications, especially in complex anatomies. The cost of endografts is high, with hospitals citing device expenses as a barrier to adoption. Reimbursement challenges also exist, with up to 34% of centres reporting financial strain in offering EVAR. Centres with lower volumes (<20 EVARs annually) show poorer outcomes and higher complication rates, further restricting widespread adoption in smaller hospitals.

OPPORTUNITY

"Technological innovations in fenestrated and percutaneous EVAR."

Fenestrated and branched EVAR procedures have grown six-fold in the last decade, rising from 335 cases in 2011 to more than 2,100 annually. Percutaneous EVAR adoption is expanding due to faster recovery, with hospitals reporting recovery periods reduced by 40% compared to traditional EVAR. Imaging advancements, including 3D mapping and simulation, are enabling tailored graft designs, improving outcomes in complex anatomies. Ambulatory surgical centres, which currently conduct 25% of procedures, are projected to grow rapidly as device profiles shrink and procedural efficiency increases.

CHALLENGE

"Anatomical complexity and infrastructure limitations."

Patients with short or angulated aortic necks, making up nearly 15% of aneurysm cases, pose challenges for EVAR suitability. Centres with fewer than 10 EVAR cases annually often lack the experience and imaging equipment necessary for complex repairs. Regulatory approval requires extensive long-term follow-up data, with studies spanning 5–10 years to confirm device durability. In lower-income regions, hospitals face infrastructure limitations, with fewer than 10 specialized centres per country in some areas, slowing market penetration.

EVAR Market Segmentation

The EVAR Market is divided by Type (AAA, TAA) and Application (Hospitals, Clinics, Ambulatory Surgical Centres). AAA accounts for over 70% of EVAR demand, while TAA is smaller but growing. Hospitals dominate applications with 75% of procedures, followed by clinics and ambulatory surgical centres with 25% combined.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Abdominal Aortic Aneurysm (AAA): Abdominal Aortic Aneurysms (AAA) dominate the EVAR Market, representing approximately 70–75% of all EVAR procedures performed worldwide. Globally, AAA prevalence ranges from 1.3% to 8.9% in men over 65 years and around 1–2% in women of the same age group, with rupture mortality exceeding 80% if untreated. Among AAA cases, nearly 79.3% have favorable infrarenal anatomy suitable for standard EVAR devices, while approximately 20.7% require advanced solutions such as fenestrated or branched grafts. Elective AAA repair via EVAR accounts for about 65–70% of all AAA surgeries, with open repair declining to less than 30–35%. Patient outcomes with EVAR show perioperative mortality of around 1–2%, compared to 4–5% for open repair. Imaging follow-up rates approach 100% at 1, 6, and 12 months, then annually, contributing to recurring demand for monitoring infrastructure in the EVAR Market.

The Abdominal Aortic Aneurysm (AAA) segment in the Endovascular Aneurysm Repair (EVAR) Market is valued at USD 2217.9 million in 2025, projected to reach USD 3730.1 million by 2034, holding a 70% market share at 6.1% CAGR.

Top 5 Major Dominant Countries in the AAA Segment

• United States: Market size USD 665.3 million in 2025, share 30%, CAGR 6.2%, supported by high AAA prevalence in patients above 65 years and advanced stent-graft availability.
• Germany: Market size USD 332.7 million in 2025, share 15%, CAGR 6.1%, driven by universal screening programs for AAA in men above 65 years.
• China: Market size USD 310.5 million in 2025, share 14%, CAGR 6.3%, fueled by aging population and expanded adoption of minimally invasive vascular procedures.
• Japan: Market size USD 243.9 million in 2025, share 11%, CAGR 6.0%, growth led by advanced hybrid operating rooms and imaging technology.
• United Kingdom: Market size USD 221.7 million in 2025, share 10%, CAGR 6.1%, due to national screening initiatives and increased elective EVAR adoption.

Thoracic Aortic Aneurysm (TAA): Thoracic Aortic Aneurysms (TAA) account for roughly 25–30% of EVAR procedures globally, with prevalence estimates of 6–10 cases per 100,000 people annually. TAA is more complex, with higher procedural risk, but EVAR adoption is growing due to its reduced invasiveness compared to open thoracic repair, which has historically carried perioperative mortality of 7–10%. EVAR for TAA, often referred to as TEVAR (Thoracic Endovascular Aneurysm Repair), now represents about 55–60% of elective TAA repairs, up from less than 40% a decade ago.

The Thoracic Aortic Aneurysm (TAA) segment is valued at USD 950.5 million in 2025, forecasted to reach USD 1598.6 million by 2034, representing 30% share of the EVAR Market at a 5.6% CAGR.

Top 5 Major Dominant Countries in the TAA Segment

• United States: Market size USD 285.1 million in 2025, share 30%, CAGR 5.7%, demand driven by TEVAR procedures replacing traditional open thoracic repair.
• China: Market size USD 190.1 million in 2025, share 20%, CAGR 5.9%, supported by increasing hospital capacity and thoracic device approvals.
• Germany: Market size USD 142.5 million in 2025, share 15%, CAGR 5.5%, benefiting from high hospital-based adoption of advanced stent grafts.
• Japan: Market size USD 114.0 million in 2025, share 12%, CAGR 5.4%, linked to complex thoracic aortic disease prevalence and technological integration.
• France: Market size USD 95.0 million in 2025, share 10%, CAGR 5.6%, driven by government support for minimally invasive aneurysm repair.

BY APPLICATION

Hospitals: Hospitals perform the majority of EVAR procedures, accounting for approximately 75% of global case volume, with high-volume centres reporting median annual volumes near 40 EVAR procedures (IQR 21–65), and some tertiary centres exceeding 76 procedures/year. Hospitals manage the full spectrum of EVAR complexity: standard infrarenal cases (~79.3% of AAA anatomy) and complex pararenal/juxtarenal cases (~20.7%) that require fenestrated or branched endografts.

Hospitals dominate the EVAR Market with USD 2217.9 million in 2025, projected at USD 3730.1 million by 2034, holding 70% share at a 6% CAGR, as tertiary centers conduct the majority of AAA and TAA EVAR procedures.

Top 5 Major Dominant Countries in the Hospital Application

• United States: USD 665.3 million in 2025, share 30%, CAGR 6.1%, hospitals perform over 75% of AAA EVAR procedures nationwide.
• Germany: USD 332.7 million in 2025, share 15%, CAGR 6.0%, hospitals lead in hybrid surgical rooms supporting EVAR growth.
• China: USD 310.5 million in 2025, share 14%, CAGR 6.2%, large public hospitals dominate procedure volumes.
• Japan: USD 243.9 million in 2025, share 11%, CAGR 6.1%, advanced vascular centres drive procedural growth.
• United Kingdom: USD 221.7 million in 2025, share 10%, CAGR 6.0%, NHS hospitals remain central for EVAR adoption.

Clinics (Vascular & Specialty Clinics): Specialty clinics and vascular surgery centres currently contribute a modest but growing portion of EVAR activity—roughly 10–15% of procedures in many markets—with medium-volume clinics performing between 10 and 30 EVARs per year. Clinics typically select patients with favorable anatomy (short femoral access, suitable aortic neck), handling mainly infrarenal AAA cases (~79% of clinic caseload) and fewer pararenal or thoracic cases (~<21%).

The Clinics application is valued at USD 633.7 million in 2025, expected to reach USD 1065.7 million by 2034, with 20% market share and a 5.8% CAGR, largely handling low-complexity EVAR procedures.

Top 5 Major Dominant Countries in the Clinics Application

• United States: USD 190.1 million in 2025, share 30%, CAGR 5.9%, vascular clinics increasing outpatient EVAR cases.
• Germany: USD 95.0 million in 2025, share 15%, CAGR 5.7%, specialty vascular clinics expanding.
• China: USD 88.7 million in 2025, share 14%, CAGR 5.8%, outpatient EVAR adoption growing.
• Japan: USD 69.7 million in 2025, share 11%, CAGR 5.7%, vascular specialty centres rising.
• France: USD 63.3 million in 2025, share 10%, CAGR 5.8%, private clinics support EVAR expansion.

Ambulatory Surgical Centres (ASCs): Ambulatory Surgical Centres (ASCs) are an emerging EVAR setting, currently performing about 10–15% of elective EVARs in advanced markets, with adoption increasing annually as device profiles shrink and percutaneous techniques rise; individual ASCs report 5–40 EVAR procedures/year depending on referral patterns. ASCs focus on low-risk, infrarenal EVAR candidates (around >85% of ASC cases) and require percutaneous access proficiency; same-day discharge rates in ASCs can reach 60–70% for selected patients compared with <30% in traditional inpatient settings.

ASCs represent USD 316.8 million in 2025, rising to USD 532.9 million by 2034, with 10% share and 6.1% CAGR, supported by percutaneous EVAR advancements and same-day discharge pathways.

Top 5 Major Dominant Countries in the ASC Application

• United States: USD 95.0 million in 2025, share 30%, CAGR 6.1%, ASCs increasingly perform outpatient EVAR.
• Germany: USD 47.5 million in 2025, share 15%, CAGR 6.0%, ambulatory vascular facilities expanding.
• China: USD 44.4 million in 2025, share 14%, CAGR 6.1%, adoption of percutaneous EVAR supporting ASC growth.
• Japan: USD 34.8 million in 2025, share 11%, CAGR 6.0%, same-day EVAR pathways rising.
• United Kingdom: USD 31.6 million in 2025, share 10%, CAGR 6.0%, ASCs growing in NHS-private partnerships.

Regional Outlook for the EVAR Market

North America leads with 40.2% global EVAR share, followed by Europe at 32%. Asia-Pacific contributes 20%, while Middle East & Africa hold 7.8%. In the USA, over 70% of AAA repairs are EVAR-based, with median centre volumes of 40 procedures annually. Europe follows similar patterns with wide variation, from 7 to 76 procedures per centre. Asia-Pacific shows rapid growth, with China and India expanding EVAR infrastructure. Middle East & Africa adoption remains limited, with hospitals conducting fewer than 20 cases annually in most countries.

NORTH AMERICA

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America holds approximately 40.2% of the global EVAR market. In the USA, 70% of AAA repairs are performed using EVAR, while open surgery accounts for less than 30%. Median centre volumes are around 40 cases annually, with some hospitals conducting up to 76 EVARs per year. Infrarenal AAA comprises 79.3% of cases, with pararenal at 20.7%. Endografts dominate device share at 58.9%, while ancillary delivery systems account for the remainder. Intact AAA cases dominate EVAR usage, comprising 65.4%, while ruptured aneurysms represent 29.1%. Hospitals remain the largest providers, handling 75% of EVAR demand, while ambulatory surgical centres manage the rest.

The North America EVAR Market is valued at USD 1140.6 million in 2025, expected to reach USD 1916.7 million by 2034, holding 36% global share with a 6% CAGR, supported by strong hospital infrastructure and high AAA prevalence.

North America - Major Dominant Countries in the EVAR Market

• United States: USD 950.5 million in 2025, share 83%, CAGR 6.1%, leads globally with highest EVAR volumes.
• Canada: USD 142.5 million in 2025, share 12.5%, CAGR 5.9%, driven by national AAA screening.
• Mexico: USD 47.5 million in 2025, share 4.1%, CAGR 6.2%, adoption in private hospitals growing.
• Cuba: USD 11.4 million in 2025, share 1%, CAGR 5.8%, expanding tertiary vascular programs.
• Dominican Republic: USD 9.6 million in 2025, share 0.8%, CAGR 6.0%, emerging vascular care services.

EUROPE

Europe contributes approximately 32% of the global EVAR market, with wide adoption across Germany, France, Italy, and the UK. EVAR accounts for nearly 70% of AAA procedures across the region. Case volumes vary widely, with some centres performing as few as 7 cases annually, while high-volume centres exceed 60 cases per year. Infrarenal AAA remains the largest segment at 79.3%, while pararenal accounts for 20.7%. Hospitals manage more than 80% of EVAR procedures, while ambulatory centres remain limited. Complication rates vary with case volume, with centres conducting fewer than 20 EVARs annually reporting higher endoleak incidences.

The Europe EVAR Market is valued at USD 1014.0 million in 2025, projected to reach USD 1701.9 million by 2034, holding 32% share at 5.9% CAGR, supported by AAA screening and advanced stent graft adoption.

Europe - Major Dominant Countries in the EVAR Market

• Germany: USD 304.2 million in 2025, share 30%, CAGR 6.0%, largest EVAR contributor in Europe.
• United Kingdom: USD 243.9 million in 2025, share 24%, CAGR 5.9%, NHS screening programs driving volume.
• France: USD 202.1 million in 2025, share 20%, CAGR 5.8%, government-funded vascular care expanding.
• Italy: USD 142.5 million in 2025, share 14%, CAGR 6.0%, hybrid centers growing.
• Spain: USD 121.3 million in 2025, share 12%, CAGR 5.8%, private-public vascular expansion ongoing.

ASIA-PACIFIC

Asia-Pacific represents around 20% of the global EVAR market and is the fastest-growing region. In China, over 21% of the global EVAR device demand is concentrated, while India represents 10%. Japan and South Korea report high procedure adoption rates. Infrarenal AAA accounts for 78–80% of EVAR cases across Asia-Pacific, while pararenal aneurysms account for 20–22%. Hospitals manage most cases, averaging 30–40 procedures annually in large centres. Device availability and regulatory approval influence growth, with endografts representing 58.9% of total demand.

The Asia EVAR Market stands at USD 760.4 million in 2025, expected to hit USD 1280.1 million by 2034, holding 24% share with 6.2% CAGR, fueled by rapid hospital growth and aging demographics.

Asia - Major Dominant Countries in the EVAR Market

• China: USD 243.9 million in 2025, share 32%, CAGR 6.3%, leading in patient volume.
• Japan: USD 190.1 million in 2025, share 25%, CAGR 6.1%, strong vascular infrastructure.
• India: USD 142.5 million in 2025, share 19%, CAGR 6.4%, demand rising in tier-1 hospitals.
• South Korea: USD 95.0 million in 2025, share 12.5%, CAGR 6.0%, advanced surgical technologies.
• Australia: USD 76.0 million in 2025, share 10%, CAGR 6.1%, increasing elective EVAR adoption.

MIDDLE EAST & AFRICA

Middle East & Africa account for 7.8% of the global EVAR market. Hospitals dominate, as ambulatory centres remain underdeveloped. Average EVAR volumes per centre remain low, often fewer than 20 cases annually, limiting surgeon experience. Infrarenal AAA represents 79% of procedures, with pararenal aneurysms limited due to device shortages. Complication rates are higher in centres performing fewer than 10 EVAR cases per year. Countries like Saudi Arabia, UAE, and South Africa are investing heavily in vascular surgery infrastructure, creating opportunities for growth.

The Middle East & Africa EVAR Market is valued at USD 253.4 million in 2025, projected at USD 429.9 million by 2034, holding 8% share with 5.8% CAGR, supported by tertiary hospitals in GCC and South Africa.

Middle East & Africa - Major Dominant Countries in the EVAR Market

• Saudi Arabia: USD 76.0 million in 2025, share 30%, CAGR 5.9%, expanding vascular care in tertiary hospitals.
• South Africa: USD 63.3 million in 2025, share 25%, CAGR 5.7%, leading EVAR adoption in Africa.
• UAE: USD 50.6 million in 2025, share 20%, CAGR 5.9%, advanced private hospital adoption.
• Egypt: USD 38.0 million in 2025, share 15%, CAGR 5.8%, AAA screening expanding.
• Turkey: USD 25.3 million in 2025, share 10%, CAGR 6.0%, bridging Europe-Middle East vascular adoption.

List of Top EVAR Companies

• Cook Group
• Braile Biomedica
• Cardinal Health
• JOTEC GmbH
• Terumo Corporation
• L. Gore & Associates
• Microport
• Medtronic
• Nano Endoluminal

Medtronic: Holds the largest share with extensive endograft and delivery system portfolio, conducting tens of thousands of cases annually worldwide.

Cook Group: Among the top competitors, with significant market penetration in fenestrated and branched EVAR, serving hospitals and specialty centres globally.

Investment Analysis and Opportunities

Investments in the EVAR market are focused on expanding access, improving device design, and upgrading imaging infrastructure. Over 75% of EVAR procedures are currently hospital-based, but investment in ambulatory surgical centres is growing. Low-profile delivery systems that allow access in smaller vessels are being heavily funded, with adoption increasing in Asia-Pacific where vessel diameters are smaller. Complex graft procedures such as fenestrated and branched EVAR are seeing increased investments, with annual case volumes rising from 335 in 2011 to more than 2,100 in 2023. Imaging technologies, including 3D simulation tools, are also attracting capital investments to improve preoperative planning and reduce endoleak incidences.

New Product Development

Product development in EVAR is focused on enhancing graft durability, reducing endoleak rates, and enabling percutaneous procedures. New endografts with hydrophilic coatings are being launched to minimize insertion resistance. Devices are being designed with active sealing systems to reduce type I and type II endoleaks, which occur in 10–20% of cases. Thoracic EVAR devices with branched and fenestrated designs are expanding, enabling treatment of complex thoracic anatomies. Customizable grafts are growing in use, with annual adoption of fenestrated EVAR increasing from 335 cases in 2011 to more than 2,100 today. Imaging software for preoperative simulation is being adopted in centres performing more than 40 EVAR procedures annually, improving precision and outcomes.

Five Recent Developments

• EVAR procedures accounted for 70% of AAA repairs globally in 2024.
• Intact AAA EVAR cases represented 65.4%, with ruptured AAA at 29.1%.
• Fenestrated and branched EVAR increased sixfold, from 335 cases in 2011 to over 2,100 in 2023.
• Endografts held 58.9% of total device share, delivery systems accounted for the rest.
• Median hospital volumes ranged between 7 and 76 EVAR cases annually, depending on regional capacity.

Report Coverage of EVAR Market

This EVAR Market Report provides comprehensive coverage of the global landscape, analyzing procedure volumes, device types, anatomical segmentation, and end-user applications. It highlights two major types of aneurysms: Abdominal Aortic Aneurysm (AAA), which dominates with 70% share, and Thoracic Aortic Aneurysm (TAA), which is smaller but growing. Device segmentation shows endografts leading with 58.9% of the global share, supported by delivery systems and ancillary devices. By application, hospitals perform 75% of EVAR procedures, with clinics and ambulatory surgical centres contributing 25% combined. Regional insights detail North America’s leadership with 40.2% share, Europe’s strong 32%, Asia-Pacific’s rapid growth with 20%, and Middle East & Africa’s 7.8% share. Key market findings include infrarenal aneurysms representing 79.3% of treated cases and pararenal aneurysms at 20.7%. The report also profiles top competitors, including Medtronic and Cook Group, who dominate global supply. It covers latest trends such as fenestrated and branched EVAR growth, percutaneous procedures, and imaging advancements. The scope includes EVAR Market Size, EVAR Market Forecast, EVAR Market Trends, EVAR Market Insights, and EVAR Market Opportunities, ensuring strategic value for stakeholders and investors.

Endovascular Aneurysm Repair (EVAR) Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 3357.94 Million in 2026
Market Size Value By	USD 5657.72 Million by 2035
Growth Rate	CAGR of 5.95% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Abdominal Aortic Aneurysm (AAA) Thoracic Aortic Aneurysm (TAA) By Application : Hospitals Clinics Ambulatory Surgical Centres
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample